salicylic acid Report issue

Small molecule Approved
AACT ChEMBL DrugBank Drug Central MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Calcium salicylate is the calcium salt of salicylic acid. The anti-cancer effectiveness of calcium salicylate has been investigated on human HT-1080 fibrosarcoma cell lines. Low calcium salicylate concentrations did not retard tumor growth progression significantly but its cytotoxic characteristics were proven to be prominent by various morphological and immunocytological techniques - approximately 25% apoptosis after treatment with calcium salicylate. This compound up-regulated the expression of p53, p21 and Bax, and down-regulated Bcl-2 in HT-1080 cells. In addition, calcium salicylate is used in root canal filling material development.   NCATS

Chemistry

  • SMILES: [Ca++].OC1=C(C=CC=C1)C([O-])=O.OC2=C(C=CC=C2)C([O-])=O
  • InChIKey: VBIGULIJWJPALH-UHFFFAOYSA-L
  • Mol. Mass: 314.304
  • ALogP: 1.09
  • ChEMBL Molecules:
    salicylic acid  
    sodium salicylate  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.1856 - $26.7780
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

2-carboxyphenol | 2-hydroxy-benzoic acid | 2-hydroxybenzoic acid | acnisal | advanced pain relief callus removers | advanced pain relief com removers | alysine | atopiclair | bazuka | clear away wart remover | compound v | compound w | cuplex verruca | diprosalic | dr. scholl's callus removers | dr. scholl's corn removers | dr. scholl's wart remover kit | duofilm | duofilm wart remover | duoplant | edinburgh | erytex | folrex | freezone | gppe paint | ionil | ionil-plus | keralyt | mas063dp | metanium | necol | noxacorn | o-carboxyphenol | occlusal | o-hydroxybenzoic acid | phiso-clear | phytocil | posalfilin | pyralvex | salactol | salatac | salicyclic acid | salicylate | salicylic acid | salicylic acid soap | saligel | sodium salicylate | sod sal | stri-dex | thwart | toepedo | verrugon | wartex | zarzenda

Organizations (48)

Research & Development (48)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (27)

Approved Indications (7)


 

Arthritis (approved 2008)

Back Pain (approved 2008)

Contusions (approved 2008)

Ichthyosis Vulgaris (approved 2012)

Keratoderma, Palmoplantar (approved 2012)

Psoriasis (approved 2012)

Sprains and Strains (approved 2008)

Experimental Indications - Clinical Trial Phases 1-4 (23)


 

Acne Vulgaris (Phase 4)

Contusions (Phase 3)

Dermatitis, Atopic (Phase 4)

Dermatitis, Seborrheic (Phase 4)

Healthy Volunteers (Phase 1/Phase 2)

Insulin Resistance (Phase 2/Phase 3)

Keratosis (Phase 2)

Keratosis, Actinic (Phase 3)

Leukemia (Phase 1)

Melanosis (Phase 4)

Myalgia (Phase 3)

Myelodysplastic Syndromes (Phase 1)

Myeloproliferative Disorders (Phase 1)

Pain (Phase 3)

Platelet-Rich Plasma (Phase 3)

Poisoning (Phase 2)

Psoriasis (Phase 3)

Quality of Life (Phase 4)

Skin Diseases (Phase 4)

Sprains and Strains (Phase 3)

Stroke (Phase 3)

Tendinopathy (Phase 3)

Warts (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 45
  • # of Trial Organizations: 48

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue